
News|Articles|April 1, 2008
Prostate cancer patients should not be limited to least costly therapy
A men's health group is organizing an online petition to urge Congress to rescind a CMS practice of restricting prostate cancer patients to the least costly drug alternative.
Advertisement
The Centers for Medicare & Medicaid Services should not have decided that prostate cancer patients seeking drug treatments should be given the least costly alternative (LCA). Rather they should be treated according to what the patients' own physician recommends. To protest against CMS' denial of payment for therapies that go beyond LCAs, the Men's Health Policy Center, part of the Men's Health Network (MHN), has set up an
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
Vaccine Policy in Flux: Stories Pharmacists Need to Follow
3
Pharmacists Are Essential Drivers of Opioid Stewardship Programs
4
Q&A: Pharmacists Help Patients Navigate Pneumococcal Vaccine Options
5






























